Australia's Therapeutic Good Administration has registered mAb biosimilar Inflectra (infliximab) from Hospira, the company said in a press release, noting it sets the stage for reimbursement under the country's Pharmaceutical Benefits Scheme.
A pharma industry group in Australia has warned the government that it needs to do something to relieve the high costs of drug manufacturing in the country or continue to lose exports.
Drug exports from Australia are down 30% in the past few years, trade figures show, with industry warning solutions to high manufacturing costs need to be addressed to compete or risk losing out to a growing market in Asia, the Sydney Morning Herald said.
Moving quickly to show investors a change of direction is ahead, Novogen acting Chief Executive Iain Ross announced a company-wide review of its preclinical programs less than a week after the abrupt departure of his predecessor, Graham Kelly.
The abrupt departure of Australia's Novogen Chairman Graham Kelly this week came after the jointly listed Nasdaq and Australian Stock Exchange biotech presented details of an in vivo proof of concept study for anti-tropomyosin drug candidate Anisina in July in the U.S.
Australia's Novogen, listed on the Nasdaq and Australia Stock Exchange, said CEO Graham Kelly has resigned and that Iain Ross will take an acting role in the post until a permanent appointment is made.
Australia-listed Benitec Biopharma has bought the rights to the preclinical ddRNAi-based hepatitis B therapeutic program, Hepbarna, from partner China-based Biomics Biotechnologies, branching out as it looks to raise cash on the U.S. market.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.
Wading into what has become an "argy-bargy" political issue, Merck CEO Ken Frazier gave his two cents on why Australians miss out on new drugs.